1. In Vivo

Progress in Cervical Cancer Screening

The smoke from the Pap wars is beginning to clear as Cytyc, which sells the {ThinPrep} monolayer system for screening for cervical cancer pushes ahead and NeoPath gets FDA approval to sell its automated instrument as a primary reader of Pap smears. Cytyc is doing quite well in its battle to get attractive reimbursement for its sample prep method. More problematic is NeuroMed Systems, which is struggling to maintain the interest of laboratories in its device which helps pathologists pinpoint trouble spots on Pap smears.

The smoke from the Pap wars is beginning to clear. Of the three companies with FDA-cleared approaches to cervical cancer screening, Cytyc Corp. 's gamble seems to be paying off best. NeoPath Inc. continues to fit into the "promising but not quite certain" category and the prognosis for Neuromedical Systems Inc. is poor. Two developments this month indicated just how far the situation has come.

First, Cytyc and Dianon Systems Inc. , an anatomic pathology laboratory (see"Consolidation in Diagnostics: AmeriPath vs. Dianon," IN VIVO,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By Ashley Yeo

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 
• By Sushmita Panda

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.